Bioscience of microbiota, food and health最新文献_第5页

Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II-a exploratory trial. 利福昔明对慢性肠道假性梗阻患者的疗效和安全性：一项随机、双盲、安慰剂对照的 II 期探索性试验。

Bioscience of microbiota, food and health Pub Date : 2024-01-01 Epub Date: 2023-12-27 DOI: 10.12938/bmfh.2023-080

Hidenori Ohkubo, Takaomi Kessoku, Kosuke Tanaka, Kota Takahashi, Tomohiro Takatsu, Tsutomu Yoshihara, Noboru Misawa, Keiichi Ashikari, Akiko Fuyuki, Shingo Kato, Takuma Higurashi, Kunihiro Hosono, Masato Yoneda, Toshihiro Misumi, Satoru Shinoda, Vincenzo Stanghellini, Atsushi Nakajima

{"title":"Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II-a exploratory trial.","authors":"Hidenori Ohkubo, Takaomi Kessoku, Kosuke Tanaka, Kota Takahashi, Tomohiro Takatsu, Tsutomu Yoshihara, Noboru Misawa, Keiichi Ashikari, Akiko Fuyuki, Shingo Kato, Takuma Higurashi, Kunihiro Hosono, Masato Yoneda, Toshihiro Misumi, Satoru Shinoda, Vincenzo Stanghellini, Atsushi Nakajima","doi":"10.12938/bmfh.2023-080","DOIUrl":"10.12938/bmfh.2023-080","url":null,"abstract":"Chronic intestinal pseudo-obstruction (CIPO) is a rare intractable disease with limited treatment options. Small intestinal bacterial overgrowth (SIBO) often co-occurs with several diseases, including CIPO. While rifaximin (RFX) is effective in treating SIBO, its efficacy for CIPO remains unclear. Here, we aimed to investigate the efficacy and safety of RFX in adult patients with CIPO. Twelve patients were randomly assigned to receive RFX (400 mg three times daily, n=8) or a placebo (PBO, n=4) for 4 weeks. The global symptom score for abdominal bloating (GSS-bloating) and an original whole gastrointestinal symptoms score (O-WGSS) were collected, and a glucose hydrogen breath test (GHBT) and abdominal computed tomography (CT) were performed. No significant differences were observed in the primary endpoint. GSS-bloating improved by 75% and 25% in the PBO and RFX groups, respectively, and O-WGSS improved by 25% in both groups. No significant differences were observed in secondary and other endpoints, including the SIBO eradication rate in the GHBT and small intestinal volume on CT. In a post hoc analysis of SIBO-positive patients with CIPO (4/4 and 4/8 in the PBO and RFX groups), SIBO was eradicated in 25% and 75% of the patients (PBO and RFX groups, respectively) at the end of treatment, indicating a high eradication rate in the RFX group. Furthermore, the small intestinal gas volume decreased in the RFX group, and no severe adverse events occurred. Although no significant improvements were observed in subjective indicators, RFX may be beneficial in alleviating SIBO and reducing the small intestinal gas volume in SIBO-positive patients with CIPO.","PeriodicalId":93908,"journal":{"name":"Bioscience of microbiota, food and health","volume":"43 2","pages":"135-144"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10981945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140338051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genome-based assessment of safety characteristics of Lacticaseibacillus paracasei NY1301 and genomic differences in closely related strains marketed as probiotics. 基于基因组的副乳杆菌 NY1301 安全特性评估以及作为益生菌上市的近缘菌株的基因组差异。

Bioscience of microbiota, food and health Pub Date : 2024-01-01 Epub Date: 2024-01-24 DOI: 10.12938/bmfh.2023-072

Masanori Fukao, Atsushi Oki, Shuichi Segawa

{"title":"Genome-based assessment of safety characteristics of Lacticaseibacillus paracasei NY1301 and genomic differences in closely related strains marketed as probiotics.","authors":"Masanori Fukao, Atsushi Oki, Shuichi Segawa","doi":"10.12938/bmfh.2023-072","DOIUrl":"10.12938/bmfh.2023-072","url":null,"abstract":"The probiotic attributes of Lacticaseibacillus paracasei NY1301 were comprehensively characterized, and a comparison between the closely related LcA (Actimel) and LcY (Yakult) probiotic strains was conducted using genomic tools. All strains exhibited high genetic similarity and likely shared a common ancestor; differences were primarily expressed as minor chromosomal re-arrangements, substitutions, insertions, and deletions. Compared with LcY, NY1301 exhibited 125 single-nucleotide polymorphisms. NY1301 lacked virulence factors, antibiotic resistance genes, and mutations associated with antibiotic resistance and had a 46-kbp prophage. This prophage is spontaneously induced at low levels and remains in a non-lytic state under standard culture conditions. The observed causal adaptive mutations were likely related to niche adaptation within the respective laboratory or manufacturing processes that occurred during the maintenance of the strains. However, the phenotypic effects of these genomic differences remain unclear. To validate the safety of NY1301, we conducted an open-label trial with healthy participants who consumed excessive amounts of NY1301 (3.0 × 1011 cfu) daily for 28 days. The results of this trial and those of other in vivo studies, coupled with the long history of human consumption without established risks to humans, provide strong evidence confirming the safety of NY1301.","PeriodicalId":93908,"journal":{"name":"Bioscience of microbiota, food and health","volume":"43 2","pages":"145-149"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10981942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140338052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of subchronic and mild social defeat stress on the intestinal microbiota and fecal bile acid composition in mice. 亚慢性轻度社会挫败应激对小鼠肠道微生物群和粪便胆汁酸组成的影响

IF 2.5

Bioscience of microbiota, food and health Pub Date : 2024-01-01 Epub Date: 2024-03-29 DOI: 10.12938/bmfh.2023-095

Naoko Yamagishi, Daisuke Kyoui, Naoko Moriya, Ayako Aoki-Yoshida, Tatsuhiko Goto, Atsushi Toyoda, Katsunari Ippoushi, Mari Maeda-Yamamoto, Yoshiharu Takayama, Chise Suzuki

{"title":"Effects of subchronic and mild social defeat stress on the intestinal microbiota and fecal bile acid composition in mice.","authors":"Naoko Yamagishi, Daisuke Kyoui, Naoko Moriya, Ayako Aoki-Yoshida, Tatsuhiko Goto, Atsushi Toyoda, Katsunari Ippoushi, Mari Maeda-Yamamoto, Yoshiharu Takayama, Chise Suzuki","doi":"10.12938/bmfh.2023-095","DOIUrl":"10.12938/bmfh.2023-095","url":null,"abstract":"The gut microbiota plays a crucial role in both the pathogenesis and alleviation of host depression by modulating the brain-gut axis. We have developed a murine model of human depression called the subchronic and mild social defeat stress (sCSDS) model, which impacts not only behavior but also the host gut microbiota and gut metabolites, including bile acids. In this study, we utilized liquid chromatography/mass spectrometry (LC/MS) to explore the effects of sCSDS on the mouse fecal bile acid profile. sCSDS mice exhibited significantly elevated levels of deoxycholic acid (DCA) and lithocholic acid (LCA) in fecal extracts, leading to a notable increase in total bile acids and 7α-dehydroxylated secondary bile acids. Consequently, a noteworthy negative correlation was identified between the abundances of DCA and LCA and the social interaction score, an indicator of susceptibility in stressed mice. Furthermore, analysis of the colonic microbiome unveiled a negative correlation between the abundance of CDCA and Turicibacter. Additionally, DCA and LCA exhibited positive correlations with Oscillospiraceae and Lachnospiraceae but negative correlations with the Eubacterium coprostanoligenes group. These findings suggest that sCSDS impacts the bidirectional interaction between the gut microbiota and bile acids and is associated with reduced social interaction, a behavioral indicator of susceptibility in stressed mice.","PeriodicalId":93908,"journal":{"name":"Bioscience of microbiota, food and health","volume":"43 3","pages":"260-266"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11220325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lactobacillus acidophilus CICC 6075 attenuates high-fat diet-induced obesity by improving gut microbiota composition and histidine biosynthesis. 嗜酸乳杆菌 CICC 6075 可通过改善肠道微生物群组成和组氨酸生物合成来减轻高脂饮食引起的肥胖。

IF 2.5

Bioscience of microbiota, food and health Pub Date : 2024-01-01 Epub Date: 2024-06-21 DOI: 10.12938/bmfh.2024-008

Shenyang Zhang, Shuai Yang, Yun Zhuang, Dan Yang, Xiqun Gu, Yi Wang, Zhenzhen Wang, Renjin Chen, Fuling Yan

{"title":"Lactobacillus acidophilus CICC 6075 attenuates high-fat diet-induced obesity by improving gut microbiota composition and histidine biosynthesis.","authors":"Shenyang Zhang, Shuai Yang, Yun Zhuang, Dan Yang, Xiqun Gu, Yi Wang, Zhenzhen Wang, Renjin Chen, Fuling Yan","doi":"10.12938/bmfh.2024-008","DOIUrl":"10.12938/bmfh.2024-008","url":null,"abstract":"This study aimed to investigate the potential anti-obesity efficacy of Lactobacillus acidophilus CICC 6075. The study analyzed fecal metagenomic data from 120 obese and 100 non-obese individuals. C57BL/6 mice on normal diet or high-fat diet (HFD) were treated with L. acidophilus CICC 6075 by daily oral gavage for 12 weeks, followed by evaluations of the obesity phenotype. Metagenomic analysis revealed depletion of L. acidophilus in obese individuals. Administration of L. acidophilus CICC 6075 attenuated excessive weight gain and fat accumulation and maintained the intestinal barrier in HFD-induced obese mice. Sequencing results showed that HFD hindered α- and β-diversity while reducing the relative abundance of Lactobacillus and norank_f_Muribaculaceae and significantly increasing the relative abundance of Ileibacterium. L. acidophilus CICC 6075 reversed these results and reduced the Firmicutes/Bacteroidetes ratio. Supplementation of L. acidophilus CICC 6075 enhanced histidine biosynthesis, inhibited the NF-κB pathway, and significantly reduced the expression levels of inflammatory factors in adipose tissue. These results indicate that L. acidophilus CICC 6075 alleviates HFD-induced obesity in mice by inhibiting the activation of the NF-κB pathway and enhancing gut microbiota functionality. This suggests that L. acidophilus CICC 6075 may be a good candidate probiotic for preventing obesity.","PeriodicalId":93908,"journal":{"name":"Bioscience of microbiota, food and health","volume":"43 4","pages":"367-380"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differences in the human gut microbiota with varying depressive symptom severity scores. 人类肠道微生物群与不同抑郁症状严重程度评分的差异。

IF 2.5

Bioscience of microbiota, food and health Pub Date : 2024-01-01 Epub Date: 2024-06-12 DOI: 10.12938/bmfh.2023-049

Yuka Masamura, Ryuichi Kubo, Yuki Midorikawa, Natsuko O Shinozaki, Satoshi Watanabe, Sayumi Maekawa, Aya K Takeda, Tazro Ohta

{"title":"Differences in the human gut microbiota with varying depressive symptom severity scores.","authors":"Yuka Masamura, Ryuichi Kubo, Yuki Midorikawa, Natsuko O Shinozaki, Satoshi Watanabe, Sayumi Maekawa, Aya K Takeda, Tazro Ohta","doi":"10.12938/bmfh.2023-049","DOIUrl":"10.12938/bmfh.2023-049","url":null,"abstract":"Depression is a prevalent mental health disorder, and its incidence has increased further because of the coronavirus disease 2019 (COVID-19) pandemic. The gut microbiome has been suggested as a potential target for mental health treatment because of the bidirectional communication system between the brain and gastrointestinal tract, known as the gut-brain axis. We aimed to investigate the relationship between the human gut microbiome and depression screening by analyzing the abundance and types of microbiomes among individuals living in Japan, where mental health awareness and support may differ from those in other countries owing to cultural factors. We used a data-driven approach to evaluate the gut microbiome of participants who underwent commercial gut microbiota testing services and completed a questionnaire survey that included a test for scoring depressive tendencies. Our data analysis results indicated that no significant differences in gut microbiome composition were found among the groups based on their depression screening scores. However, the results also indicated the potential existence of a few differentially abundant bacterial taxa. Specifically, the detected bacterial changes in abundance suggest that the Bifidobacteriaceae, Streptococcaceae, and Veillonellaceae families are candidates for differentially abundant bacteria. Our findings should contribute to the growing body of research on the relationship between gut microbiome and mental health, highlighting the potential of microbiome-based interventions for depression treatment. The limitations of this study include the lack of clear medical information on the participants' diagnoses. Future research could benefit from a larger sample size and more detailed clinical information.","PeriodicalId":93908,"journal":{"name":"Bioscience of microbiota, food and health","volume":"43 4","pages":"336-341"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The prebiotic effect of 1-kestose in low-birth-weight neonates taking bifidobacteria: a pilot randomized trial in comparison with lactulose. 1-kestose 对服用双歧杆菌的低出生体重新生儿的益生效应：与乳果糖比较的试点随机试验。

IF 2.5

Bioscience of microbiota, food and health Pub Date : 2024-01-01 Epub Date: 2024-05-20 DOI: 10.12938/bmfh.2023-079

Saori Tanaka, Mayuko Takahashi, Kenichi Takeshita, Koo Nagasawa, Haruka Takei, Hironori Sato, Haruka Hishiki, Naruhiko Ishiwada, Hiromichi Hamada, Yoshihiro Kadota, Takumi Tochio, Tomoki Ishida, Koh Sasaki, Mika Tomita, Yoshiteru Osone, Ryo Takemura, Naoki Shimojo

{"title":"The prebiotic effect of 1-kestose in low-birth-weight neonates taking bifidobacteria: a pilot randomized trial in comparison with lactulose.","authors":"Saori Tanaka, Mayuko Takahashi, Kenichi Takeshita, Koo Nagasawa, Haruka Takei, Hironori Sato, Haruka Hishiki, Naruhiko Ishiwada, Hiromichi Hamada, Yoshihiro Kadota, Takumi Tochio, Tomoki Ishida, Koh Sasaki, Mika Tomita, Yoshiteru Osone, Ryo Takemura, Naoki Shimojo","doi":"10.12938/bmfh.2023-079","DOIUrl":"10.12938/bmfh.2023-079","url":null,"abstract":"Probiotics such as bifidobacteria have been given to low-birth-weight neonates (LBWNs) at risk for a disrupted gut microbiota leading to the development of serious diseases such necrotizing enterocolitis. Recently prebiotics such as lactulose are used together with bifidobacteria as synbiotics. However, faster and more powerful bifidobacteria growth is desired for better LBWN outcomes. The prebiotic 1-kestose has a higher selective growth-promoting effect on bifidobacteria and lactic acid bacteria in vitro among several oligosaccharides. Twenty-six premature neonates (less than 2,000 g) admitted to a neonatal intensive care unit (NICU) were randomly assigned to receive Bifidobacterium breve M16-V with either 1-kestose or lactulose once a day for four weeks from birth. A 16S rRNA gene analysis revealed similar increases in alpha-diversity from 7 to 28 days in both groups. The most dominant genus on both days was Bifidobacterium in both groups, with no significant difference between the two groups. Quantitative PCR analysis revealed that the number of Staphylococcus aureus tended to be lower in the 1-kestose group than in the lactulose group at 28 days. The number of Escherichia coli was higher in the 1-kestose group at 7 days. The copy number of total bacteria in the 1-kestose group was significantly higher than that in the lactulose group at 3 time points, 7, 14, and 28 days. No severe adverse events occurred in either group during the study period. l-Ketose may offer an alternative option to lactulose as a prebiotic to promote the development of gut microbiota in LBWNs.","PeriodicalId":93908,"journal":{"name":"Bioscience of microbiota, food and health","volume":"43 4","pages":"329-335"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An updated review on the treatment for diversion colitis and pouchitis, with a focus on the utility of autologous fecal microbiota transplantation and its relationship with the intestinal microbiota. 关于治疗转流性结肠炎和肠袋炎的最新综述，重点关注自体粪便微生物群移植的效用及其与肠道微生物群的关系。

IF 2.5

Bioscience of microbiota, food and health Pub Date : 2024-01-01 Epub Date: 2024-04-23 DOI: 10.12938/bmfh.2024-014

Kentaro Tominaga, Yuichi Kojima, Yuzo Kawata, Kazuya Takahashi, Hiroki Sato, Atsunori Tsuchiya, Kenya Kamimura, Shuji Terai

{"title":"An updated review on the treatment for diversion colitis and pouchitis, with a focus on the utility of autologous fecal microbiota transplantation and its relationship with the intestinal microbiota.","authors":"Kentaro Tominaga, Yuichi Kojima, Yuzo Kawata, Kazuya Takahashi, Hiroki Sato, Atsunori Tsuchiya, Kenya Kamimura, Shuji Terai","doi":"10.12938/bmfh.2024-014","DOIUrl":"10.12938/bmfh.2024-014","url":null,"abstract":"Diversion colitis (DC) is characterized by mucosal inﬂammation in the defunctioned segment of the colon following a colostomy or ileostomy. The major causes of DC are an increase in the number of aerobic bacteria, a lack of short-chain fatty acids (SCFAs), and immune disorders in the diverted colon. However, its exact pathogenesis remains unknown. Various treatment strategies for DC have been explored, although none have been definitively established. Treatment approaches such as SCFAs, 5-aminosalicylic acid enemas, steroid enemas, and irrigation with fibers have been attempted, yielding various degrees of efficacies in mitigating mucosal inflammation. However, only individual case reports demonstrating the limited effect of the following therapies have been published: leukocytapheresis, dextrose (hypertonic glucose) spray, infliximab, an elemental diet, and coconut oil. The usefulness of probiotics for treating DC has recently been reported. Furthermore, fecal microbiota transplantation (FMT) has emerged as a promising treatment for DC. This review provides an update on the treatment strategies of DC, with a particular focus on FMT and its relationship with the intestinal microbiota. FMT may become the first choice of treatment for some patients in the future because of its low medical costs, ease of use, and minimal side effects. Furthermore, FMT can also be used for postoperative DC prophylaxis.","PeriodicalId":93908,"journal":{"name":"Bioscience of microbiota, food and health","volume":"43 3","pages":"162-169"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11220330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Roles of flavoprotein oxidase and the exogenous heme- and quinone-dependent respiratory chain in lactic acid bacteria. 乳酸菌中黄素氧化酶和外源血红素及醌依赖性呼吸链的作用。

IF 2.5

Bioscience of microbiota, food and health Pub Date : 2024-01-01 Epub Date: 2024-05-14 DOI: 10.12938/bmfh.2024-002

Yuji Yamamoto

引用次数: 0

Effects of food containing Lactococcus lactis strain T21 on the improvement of skin condition: a randomized, double-blind, placebo-controlled, parallel-group study. 含乳球菌 T21 菌株的食物对改善皮肤状况的影响：一项随机、双盲、安慰剂对照、平行组研究。

IF 2.5

Bioscience of microbiota, food and health Pub Date : 2024-01-01 Epub Date: 2024-08-06 DOI: 10.12938/bmfh.2023-086

Kazuya Uehara, Yosuke Sunada, Sumio Kondo, Shinji Matsuo

{"title":"Effects of food containing Lactococcus lactis strain T21 on the improvement of skin condition: a randomized, double-blind, placebo-controlled, parallel-group study.","authors":"Kazuya Uehara, Yosuke Sunada, Sumio Kondo, Shinji Matsuo","doi":"10.12938/bmfh.2023-086","DOIUrl":"10.12938/bmfh.2023-086","url":null,"abstract":"This research aimed to examine the effect of daily intake of food containing Lactococcus lactis strain T21 (T21) on skin conditions and inflammation-related markers in healthy adults who experience itching because of dry skin and have an atopic predisposition. A randomized, double-blind, placebo-controlled parallel-group study was conducted on 44 subjects aged 20 to 64 years. Subjects were randomly assigned to receive a T21-containing food or placebo daily for 8 weeks. The hydration of stratum corneum, trans-epidermal water loss, skin brightness (L*), skin redness (a*), and quality of life (QOL) scores were evaluated. Moreover, SCCA2, Th1/Th2, peripheral blood eosinophil count, TGF-β1, TARC, total IgE, and LDH were measured as inflammation-related markers. The results showed that, compared with the placebo, food containing T21 reduced trans-epidermal water loss in the neck and increased neck skin brightness (L*) after 8 weeks of consumption. Furthermore, a stratified analysis in subjects with a history of atopy showed improvements in neck skin redness (a*) and skin-related QOL. No significant improvement in inflammation-related markers was observed. Intake of food containing T21 for 8 weeks in healthy adult with atopic predisposition was suggested to improve skin barrier function in the neck and brightness in the neck skin. Furthermore, the results also suggested that it had the effect of improving rough skin and reducing discomfort due to dryness in healthy adults with a history of atopy.","PeriodicalId":93908,"journal":{"name":"Bioscience of microbiota, food and health","volume":"43 4","pages":"381-390"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Continuous intake of galacto-oligosaccharides containing syrup contributes to maintaining the health of household dogs by modulating their gut microbiota. 持续摄入含半乳糖寡糖的糖浆有助于通过调节家犬的肠道微生物群来保持它们的健康。

IF 2.5

Bioscience of microbiota, food and health Pub Date : 2024-01-01 Epub Date: 2024-02-20 DOI: 10.12938/bmfh.2023-062

Atsuko Hokkyo, Sayaka Kakiyama, Yuh Shiwa, Chiaki Kaga, Toshihide Kobayashi, Koji Nomoto, Naomi Harima-Mizusawa

{"title":"Continuous intake of galacto-oligosaccharides containing syrup contributes to maintaining the health of household dogs by modulating their gut microbiota.","authors":"Atsuko Hokkyo, Sayaka Kakiyama, Yuh Shiwa, Chiaki Kaga, Toshihide Kobayashi, Koji Nomoto, Naomi Harima-Mizusawa","doi":"10.12938/bmfh.2023-062","DOIUrl":"10.12938/bmfh.2023-062","url":null,"abstract":"Interest is growing in the relationship of the microbiota and intestinal environment with health in companion animals. Galacto-oligosaccharides (GOS), typical prebiotics, are expected to provide benefits in dogs. Previous studies of GOS in dogs have involved dogs with similar rearing conditions and diets, which may have biased the results. We conducted an open study of 26 healthy dogs kept in households with diverse rearing environments in order to evaluate how the intake of a GOS-containing syrup affects the intestinal microbiota and its metabolites. Each dog was fed 1.2-4.8 g of the GOS-containing syrup (GOS 0.5-2.0 g equivalent) for 8 weeks. Fecal microbiota, fecal concentrations of organic acids and putrefactive products, fecal odor, and serum uremic toxin concentrations were evaluated before intake (0 weeks), during the 8-week intake period (4 and 8 weeks), and 4 weeks after intake (12 weeks). The activity of N-benzoyl-DL-arginine peptidase in dental plaque, which may be associated with periodontal disease, was evaluated at 0 and 8 weeks. Continuous intake of GOS resulted in changes in fecal microbiota, with a particularly marked increase in the abundance of Megamonas, which produces propionic acid. Other findings included a significant increase in the fecal acetic, propionic, and n-butyric acid concentrations. Additionally, significant decreases in fecal odor, fecal phenol concentration, and serum indoxyl sulfate concentration. Intake of GOS was also associated with a significant decrease in N-benzoyl-DL-arginine peptidase activity in dental plaques. These results suggest that continuous intake of GOS may contribute to canine health.","PeriodicalId":93908,"journal":{"name":"Bioscience of microbiota, food and health","volume":"43 3","pages":"204-212"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11220336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0